Table 2.
Management of Patients With Myocardial Injury During Initial Hospital Admission, Stratified by Sex and Study Phase
| Overall (N = 10,360) | Women |
Men |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall (N = 4,991) | Validation (n = 2,072) | Implementation (n = 2,919) | p Value∗ | Overall (N = 5,369) | Validation (n = 2,044) | Implementation (n = 3,325) | p Value∗ | ||
| Duration of stay, h | 74 (23–165) | 76 (21–186) | 71 (8–195) | 79 (28–177) | <0.001 | 73 (26–146)† | 75 (14–153) | 72 (31–142) | 0.247 |
| Coronary angiography | 3,425 (33) | 1,120 (22) | 367 (18) | 753 (26) | <0.001 | 2,305 (43)† | 770 (38) | 1,535 (46) | <0.001 |
| PCI | 2,162 (21) | 624 (13) | 194 (9) | 430 (15) | <0.001 | 1,538 (29)† | 472 (23) | 1,066 (32) | <0.001 |
| CABG | 158 (2) | 31 (1) | 11 (1) | 20 (1) | 0.617 | 127 (2)† | 54 (3) | 73 (2) | 0.341 |
| PCI or CABG | 2,315 (22) | 654 (13) | 205 (10) | 449 (15) | <0.001 | 1,661 (31)† | 524 (26) | 1,137 (34) | <0.001 |
| New antiplatelet drug | 4,094 (40) | 1,580 (32) | 595 (29) | 985 (34) | <0.001 | 2,514 (47)† | 877 (43) | 1,637 (49) | <0.001 |
| New DAPT | 3,383 (33) | 1,225 (25) | 453 (22) | 772 (26) | <0.001 | 2,158 (40)† | 726 (36) | 1,432 (43) | <0.001 |
| New statin therapy | 2,034 (20) | 704 (14) | 237 (11) | 467 (16) | <0.001 | 1,330 (25)† | 455 (22) | 875 (26) | 0.001 |
| New ACE inhibitor or ARB | 1,945 (19) | 685 (14) | 255 (12) | 430 (15) | 0.016 | 1,260 (24)† | 450 (22) | 810 (24) | 0.055 |
| New beta-blocker | 2,559 (25) | 960 (19) | 322 (16) | 638 (22) | <0.001 | 1,599 (30)† | 571 (28) | 1,028 (31) | 0.023 |
| New oral anticoagulant agent | 643 (6) | 313 (6) | 119 (6) | 194 (7) | 0.216 | 330 (6) | 117 (6) | 213 (6) | 0.346 |
Values are median (interquartile range) or n (%).
DAPT = dual-antiplatelet therapy; other abbreviations as in Table 1.
∗
Chi-square and Mann-Whitney U-tests comparing the validation and implementation phases.
†
p < 0.05 comparing women and men.